

FEDERICA LOSCOCCO, BS, PhD

Jun 2017

PERSONAL DATA

Date and Place of Birth: February, 10th 1980; Pesaro(Italy)

Permanent Address:

*via Bonini, 147
61122 Pesaro
ITALY*

(+39) 328 4929449 Mobile

E-mail: federica.loscocco@gmail.com

Professional Address:

*Hematology and Stem Cell
Transplant Center
Marche Nord Hospital
via Lombroso, 1
61122Pesaro
ITALY*

(+39) 0721 364022 Phone
(+39) 0721 364052 Fax

EDUCATION

*Current professional
position, october 2008*

Clinical Trial Manager

Hematology and Stem Cell Transplant Center, Marche Nord Hospital,
Pesaro, Italy

January 2010

PhD, Immunometabolic, Degenerative and Infective Diseases.

Institute of Clinical Specialized and Odontostomatologic Science
Children's Hospital "Salesi"– University of Ancona, Italy

October 2009

Advanced statistics course

University "Carlo Bo" of Urbino, Italy

October 2006

Master in Biotechnology

Institute of Biotechnology –Fano
University "Carlo Bo" of Urbino, Italy

July 2005

Degree in Biological Science, summa cum laude.

University "Carlo Bo" of Urbino, Italy

2003-2005

Internship

Institute of Physiology- University "Carlo Bo" of Urbino, Italy

License in Biological Science : (Pesaro e Urbino) obtained in 2006.

**Co-author of 20 full-papers published on Journals quoted in the
Current Contest Index**

Co-author >55 abstracts published on Journals quoted in the Current Contest Index

Co-Author of 2 book chapters on Hematological subjects.

Clinical Research Coordinator in several Phase II-III clinical trials performed under GCP-ICH since 2008

RESEARCH INTERESTS

- Acute myeloid leukemia.
- Myelodysplastic Syndrome.

MEMBERSHIP IN PROFESSIONAL SOCIETIES

- Member of the European Hematology Association (EHA) since 2013.
- Member of the Italian Society for Experimental Hematology (SIES) (2011)

FOREIGN LANGUAGE SKILLS

- Italian (native speaker)
- English

SHORT BIOGRAPHY

Federica Loscocco, BS, PhD, is a Clinical Research Coordinator at Division of Hematology and Stem Cell Transplant Centre at Marche Nord Hospital (AORMN), Pesaro, Italy. She graduated magna cum laude in 2005 at the Urbino University of Biology, after 2 years internship at Institute of Physiology. Afterwards, she got a Master in Biotechnology in 2006 at the Urbino University of Biotechnology. Finally, she got her PhD in Immunometabolic, Degenerative and Infective Diseases in 2010 at the Ancona University School of Medicine. She is mainly involved in clinical trials for the treatment of acute and chronic leukemias, multiple myeloma, lymphomas and stem cell transplantation. She work strictly with physicians and statistician to manage and organize clinical trials, in accordance with GCP guidelines. She has a broad knowledge of protocols and of their administration and she has good statistical knowledge. She is involved in preparation of study documentation (protocol, synopsis, ICF...) of no-profit clinical trials and she maintains contact with clinical, biological and administrative staff participating in research studies (Ethical Committees, Sponsor, Internal Pharmacy, internal and external laboratory....). She is data entry and maintenance of selected study tracking data base. She deals of Farmacovigilance, report and follow up on serious adverse events and prepare annual report for EC and AC (EudraVigilance training course). She is coordinator of data managers activity on sponsored clinical trials in the Hospital. She is involved in budget payments and tracking systems. She is involved in Jacie quality program as data manager for hematopoietic stem cells transplantation from 2015, she manages Promise and collects and analyzes data for indicators.

She is involved as biologist in biomarkers study. She published as co-author 20 full-paper on the topic leukemia, lymphoma and stem cell transplantation in the most important international scientific Journals in Journals quoted in the Current Contest Index (Leukemia, Blood, Bone Marrow

Transplantation..). She is co-author of more 55 abstracts published on Journals quoted in the Current Contest Index and of a few Chapter of books on hematological malignancies.

She is a member of: European Hematology Association (EHA) and Italian Society for Experimental Hematology (SIES)

She was awarded with Research Grant during the 13th SIES National Congress on October 2014 for the project “Genetic variants in genes involved in folate pathway, DNA methylation or repair predict overall survival in patients with low risk, untreated myelodysplastic syndrome”.

PUBLICATIONS

1. Genetic profiling in acute myeloid leukemia: a path to predicting treatment outcome. Visani G, **Loscocco F**, Isidori A, Piccaluga PP. *Expert Rev Hematol*. 2018 May 24;1-7. doi: 10.1080/17474086.2018.1475225. [Epub ahead of print]
2. Iron toxicity - Its effect on the bone marrow. Isidori A, Borin L, Elli E, Latagliata R, Martino B, Palumbo G, Pilo F, **Loscocco F**, Visani G, Cianciulli P. *Blood Rev*. 2018 Apr 13. pii: S0268-960X(17)30150-9. doi: 10.1016/j.blre.2018.04.004. [Epub ahead of print] Review.
3. MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine. Visani G, **Loscocco F**, Ruzzo A, Galimberti S, Graziano F, Voso MT, Giacomini E, Finelli C, Ciabatti E, Fabiani E, Barulli S, Volpe A, Magro D, Piccaluga P, Fuligni F, Vignetti M, Fazi P, Piciocchi A, Gabucci E, Rocchi M, Magnani M, Isidori A. *Pharmacogenomics J*. 2018 May 22;18(3):444-449. doi: 10.1038/tj.2017.48. Epub 2017 Dec 5.
4. The *hOCT1* and *ABCB1* polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. Galimberti S, Bucelli C, Arrigoni E, Baratè C, Grassi S, Ricci F, Guerrini F, Ciabatti E, Fava C, D'Avolio A, Fontanelli G, Cambrin GR, Isidori A, **Loscocco F**, Caocci G, Greco M, Bocchia M, Aprile L, Gozzini A, Scappini B, Cattaneo D, Scortechini AR, La Nasa G, Bosi A, Leoni P, Danesi R, Saglio G, Visani G, Cortelezzi A, Petrini M, Iurlo A, Di Paolo A. *Oncotarget*. 2017 Sep 30;8(50):88021-88033. doi: 10.18632/oncotarget.21406. eCollection 2017 Oct 20.
5. Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study. Visani G, Ferrara F, Di Raimondo F, **Loscocco F**, Fuligni F, Paolini S, Zammit V, Spina E, Rocchi M, Visani A, Piccaluga PP, Isidori A. *Leuk Res*. 2017 Nov;62:77-83. doi: 10.1016/j.leukres.2017.09.019. Epub 2017 Sep 25.
6. Visani G, Manti A, Valentini L, Canonico B, **Loscocco F**, Isidori A, Gabucci E, Gobbi P, Montanari S, Rocchi M, Papa S, Gatti AM. Environmental nanoparticles are significantly over-expressed in acute myeloid leukemia. *Leuk Res*. 2016 Nov; 50:50-56. doi: 10.1016
7. Isidori A, **Loscocco F**, Visani G. AML therapy in the elderly: a time for a change. *Expert Opin Drug Saf*. 2016 Apr 7.
8. Isidori A, **Loscocco F**, Malerba L, Clissa C, Guiducci B, Visani G. Enteric-coated mycophenolate sodium containing: a new option for GHVD prophylaxis? *Eur J Haematol*. 2016 Jan 22. doi: 10.1111/ejh.12739.

9. Isidori A, **Loscocco F**, Guiducci B, Malerba L, Clissa C, Visani G. PBSC mobilization in patients with autoimmune diseases: what's next. *Eur J Haematol*. 2015 Nov 14 doi: 10.1111/ejh.12701.
10. Isidori A, Clissa C, **Loscocco F**, Guiducci B, Barulli S, Malerba L, Gabucci E, Visani. Advancement in high dose therapy and autologous stem cell rescue in lymphoma. *World J Stem Cells*. 2015 Aug 26;7(7):1039-46. doi: 10.4252/wjsc.v7.i7.1039. Review.
11. Visani G, **Loscocco F**, Isidori A. Nanocarriers targeting cancer stem cells: how to help drugs to find their way home. *Nanomedicine (Lond)*. 2015;10(7):1043-6. doi: 10.2217/nnm.15.8.
12. Visani G, **Loscocco F**, Isidori A. Nanomedicine strategies for hematological malignancies: what's next. *Nanomedicine (Lond)*. 2014 Oct;9(15):2415-28. doi: 10.2217/nnm.14.128. Review
13. Visani G, Stefani PM, Capria S, Malerba L, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Gonella R, Gobbi M, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, **Loscocco F**, Isidori A. Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. *Blood*. 2014 Nov 6;124(19):3029-31.
14. Isidori A, Salvestrini V, Ciciarello M, **Loscocco F**, Visani G, Parisi S, Lecciso M, Ocadlikova D, Rossi L, Gabucci E, Clissa C, Curti A. The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment. *Expert Rev Hematol*. 2014 Sep 16:1-12
15. Visani G, Malagola M, Guiducci B, Lucesole M, **Loscocco F**, Gabucci E, Paolini S, Piccaluga PP, Isidori A. Conditioning regimens in acute myeloid leukemia. *Expert Rev Hematol*. 2014 Aug;7(4):465-79.
16. Visani G, Ferrara F, Di Raimondo F, **Loscocco F**, Sparaventi G, Paolini S, Fuligni F, Gazzola A, Rossi M, Laginestra MA, Caraci MR, Riccardi C, Rocchi M, Visani A, Piccaluga PP, Isidori A. Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients. *Leukemia*, 2014, Apr;28(4):967-70. Epub 2014 Jan 20.
17. Visani G, Guiducci B, Giardini C, **Loscocco F**, Ricciardi T, Isidori A. Deferasirox improves hematopoiesis after allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transpl*, 2014, Apr;49(4):585-7. Epub 2014 Jan 13.
18. Isidori A, Venditti A, Maurillo L, Buccisano F, **Loscocco F**, Manduzio P, Sparaventi G, Amadori S and Visani G. Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients. *Exp Rev Hematol*. 2013, Dec;6(6):767-84.

19. Isidori A, Piccaluga PP, **Loscocco F**, Guiducci B, Barulli S, Ricciardi T, Picardi P, Visani G. High-dose therapy followed by stem cell transplantation in Hodgkin lymphoma: past and future. *Expert Rev. Hematol.* Aug;6(4):451-64.
20. Visani G, Picardi P, Guiducci B, **Loscocco F**, Giardini C, Lucesole M, Barulli S, Ricciardi T, Isidori A. Third party cord blood transplant boosts autologous hematopoiesis in a case of persistent bone marrow aplasia after double transplant failure for B-thalassemia major. *Mediterr J Hematol Infect Dis.* 2013 Apr 15;5(1):e2013029.
21. Visani G, Picardi P, Tosi P, Gonella R, **Loscocco F**, Ricciardi T, Malerba L, Guiducci B, Tomassetti S, Barulli S, Isidori A. Autologous stem cell transplantation for aggressive lymphomas. *Mediterr J Hematol Infect Dis.* 2012;4(1):e2012075.

BOOK CHAPTERS

1. Visani G, **Loscocco F**, Ricciardi T, Picardi P, Barulli S, Guiducci B and Isidori A. The Chemical Structure, Pharmacology and Adverse Effects of Imatinib. In: *Imatinib: Chemical Structure, Pharmacology and Adverse Effects*. Akhtari M and Elhemaidi I (Ed.), Nova Publishing Group, 2013. ISBN: 978-1-62808-304-0.
2. Isidori A, **Loscocco F**, Visani G. Chemokines for Stem Cell Mobilization: What's Next . In: *New Developments in Chemokines Research*. Sands E and Silver JM (Ed.) , Nova Publishing Group, 2013. ISBN: 978-1-62808-464-1

I hereby authorise the processing of my personal data pursuant to Italian law. 196/03 on privacy and 2017/10/GDPR.

Pesaro,

Federica Loscocco